# US 2026/0070940 A1 · Stabilized immunoglobulin domains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0070940 A1
- Document ID: US20260070940A1
- Status: Published application
- Kind: A1
- Application number: 19/087,357
- Filed: 2025-03-21
- Published: 2026-03-12
- Earliest claimed: 2018-01-31
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Laura CODARRI DEAK; Stefan DENGL; Jens FISCHER; Thomas HOFER; Laurent LARIVIÈRE; Ekkehard MÖSSNER; Stefan SEEBER; Pablo UMAÑA; Anne-Claire ZAGDOUN
- Web page: https://patentgrep.com/patent/US20260070940A1

## CPC

- C07K 1/047: {Simultaneous synthesis of different peptide species; Peptide libraries}
- C07K 16/005: {constructed by phage libraries}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2881: {against CD71}
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/3053: {Skin, nerves, brain}
- C07K 16/40: against enzymes
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.

## Claims

### Claim 1

An autonomous VH domain with cysteines in positions (i) 52a and 71 or (ii) 33 and 52 according to Kabat numbering, wherein said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions.

### Claim 2 (depends on 1)

The autonomous VH domain of claim 1 comprising a substitution selected from the group consisting of 44E, 45E and (101-1)Y according to Kabat numbering.

### Claim 3 (depends on 2)

The autonomous VH domain of claim 2 comprising the substitutions 44E, 45E, and (101-1)Y according to Kabat numbering.

### Claim 4 (depends on 1)

The autonomous VH domain of claim 1 comprising a substitution selected from the group consisting of G44E, T45E and F(101-1)Y according to Kabat numbering.

### Claim 5 (depends on 4)

The autonomous VH domain of claim 4 comprising the substitutions G44E, T45E, and F(101-1)Y according to Kabat numbering.

### Claim 6 (depends on 1)

The autonomous VH domain of claim 1 comprising a heavy chain variable domain framework comprising a
(a) FR1 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 207,
(b) FR2 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208,
(c) FR3 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209, and
(d) FR4 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210;
or
(a) FR1 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 211,
(b) FR2 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 208,
(c) FR3 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 209, and
(d) FR4 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 210.

### Claim 7 (depends on 1)

The autonomous VH domain of claim 1 comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40, or SEQ ID NO: 42, or SEQ ID NO: 44, SEQ ID NO: 46, or SEQ ID: NO 180.

### Claim 8 (depends on 1)

The autonomous VH domain of claim 1 comprising the sequence of SEQ ID NO: 40, or SEQ ID NO: 42, or SEQ ID NO: 44, SEQ ID NO: 46, or SEQ ID NO: 180.

### Claim 9 (depends on 1)

The autonomous VH domain of claim 1, wherein the autonomous VH domain binds to death receptor 5 (DR5), or melanoma-associated chondroitin sulfate proteoglycan (MCSP), or transferrin receptor 1 (TfR1), or lymphocyte-activation gene 3 (LAG3), or fibroblast activation protein (FAP), or carcinoembryonic antigen (CEA), or CD28.

### Claim 10 (depends on 9)

The autonomous VH domain of claim 9,
(A) binding to MCSP, wherein the autonomous VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65;
or
(B) binding to TfR1, wherein the autonomous VH domain comprises an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 194, the sequence of SEQ ID NO: 195, the amino acid sequence of SEQ ID NO: 196, the amino acid sequence of SEQ ID NO: 197, the amino acid sequence of SEQ ID NO: 198, the amino acid sequence of SEQ ID NO: 199, the amino acid sequence of SEQ ID NO: 200;
or
(C) binding to LAG3, wherein the autonomous VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85 SEQ, ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97 or
(D) binding to FAP, wherein the autonomous VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279;
or
(E) binding to CEA, wherein the autonomous VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 300, SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313;
or
(F) binding to CD28, wherein the autonomous VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346.

### Claim 11 (depends on 1)

The autonomous VH domain of claim 1, wherein the autonomous VH domain comprises a VH3_23 human framework, particularly based on the VH framework of Herceptin® (trastuzumab).

### Claim 12 (depends on 1)

The autonomous VH domain of claim 1 fused to an Fc domain.

### Claim 13 (depends on 12)

The autonomous VH domain of claim 12 wherein the Fc domain is a human Fc domain.

### Claim 14 (depends on 12)

The autonomous VH domain of claim 12, wherein the autonomous VH domain is fused to the N-terminal or to the C-terminal end of the Fc domain.

### Claim 15 (depends on 12)

The autonomous VH domain of claim 12, wherein the Fc domain comprises a knob mutation or a hole mutation, particularly a knob mutation.

### Claim 16 (depends on 1)

A VH domain library comprising a plurality of the autonomous VH domains of claim 1.

### Claim 17 (depends on 1)

A VH domain library comprising a plurality of the autonomous VH domains of claim 1 generated from a variety of polynucleotides.

### Claim 18 (depends on 1)

A polynucleotide library comprising a plurality of polynucleotides encoding for a variety of the autonomous VH domains of claim 1.

### Claim 19 (depends on 1)

A polynucleotide encoding the autonomous VH domain of claim 1.

### Claim 20 (depends on 19)

An expression vector comprising the polynucleotide of claim 19.

### Claim 21 (depends on 20)

A host cell comprising the expression vector of claim 20.

### Claim 22 (depends on 1)

An antibody comprising the autonomous VH domain of claim 1.

### Claim 23 (depends on 16)

A method for identifying an antigen binding molecules using the VH domain library of claim 16 comprising the steps
(i) contacting the VH domain library with a target, and
(ii) identifying VH domains of the library binding to the target.

### Claim 24 (depends on 18)

A method for identifying an antigen binding molecules using the polynucleotide library of claim 18 comprising the steps
(i) expressing the polynucleotide library, particularly in a host cell,
(i) assaying the binding of the expressed VH domain library to a target, and
(ii) identifying VH domains of the expressed VH domain library binding to the target.

### Claim at position 25

25-26. (canceled)
